AngioDynamics appoints Richard Rosenzweig general counsel 

AngioDynamics, a  provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, announced that it has appointed Richard C. Rosenzweig as Senior Vice President, General Counsel, effective January 31, 2021. Mr. Rosenzweig will also serve as Corporate Secretary to the AngioDynamics Board of Directors.

Mr. Rosenzweig succeeds Stephen Trowbridge who has served as Executive Vice President, Chief Financial Officer, and General Counsel since February 2020. Mr. Trowbridge will continue in his role as Executive Vice President and Chief Financial Officer.

He joins AngioDynamics from C.R. Bard, where he served as corporate officer and Vice President, Law and completed more than 75 business development transactions. Rosenzweig has more than 20 years of experience in leadership roles providing legal guidance, governance and compliance oversight, and strategic business leadership to global medical device and health care companies, including Phibro Animal Health Corporation, Impath, Inc., and Johnson & Johnson.